While hormonal therapy has been the usual and appropriate treatment of advanced or
metastatic prostatic cancer for the past 50 years, the recent development of new therapeutic …

Prostatic cancer is the second most common malignancy in males and the third leading
cause of cancer deaths in men in the United States. It is estimated that in 1987 there were …

In most western countries, carcinoma of the prostate is the second most frequent cause of
cancer death following car-cinoma of the lung. In the pathogenesis of clinical carcinoma of …

The goals of hormonal therapy for prostatic cancer are to decrease circulating plasma
testosterone to castration levels; prevent a rise in or reduce circulating prolactin; and block …

IT IS now well established that chronic treatment with GnRH agonists offers an
advantageous alternative to orchiectomy and estrogens for the treatment of prostate cancer …

The identification of the decapeptide luteinizing hormone-releasing hormone (LHRH) has
led to the development of LHRH agonists, which are a new class of drugs for the treatment of …

In the 60 years since Huggins first demonstrated the hormone dependency of prostate
cancer, the introduction of various means of hormonal manipulation has resulted in modest …

Within the past 20 years there have been major changes in the hormonal treatment of
metastatic prostatic cancer after the cardiovascular hazard of stilboestrol was recognized …

Objectives: To evaluate the efficacy of non-steroidal anti-androgen monotherapy in the
treatment of advanced prostate cancer. Methods: The pertinent literature regarding the use …

Prostatic cancer is by far the most common hormone-sensitive tumor in men, and as such
has great potential for exploration and exploitation of hormonal and chemotherapeutic …